# A Phase I Study of Hyper-CVAD In Combination With Venetoclax In Pediatric Patients With Relapsed or Refractory Acute Leukemias That Are of the Lymphoid Lineage Including Bi-Phenotypic or Undifferentiated Leukemias

> **NCT06466395** · PHASE1 · RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 22 (estimated)

## Conditions studied

- Refractory Acute Leukemia
- Relapsed Acute Leukemia
- Undifferentiated Leukemia
- Bi-Phenotypic Leukemia

## Interventions

- **DRUG:** Venetoclax
- **DRUG:** Hyper-CVAD

## Key facts

- **NCT ID:** NCT06466395
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-18
- **Primary completion:** 2027-12-31
- **Final completion:** 2031-12-31
- **Target enrollment:** 22 (ESTIMATED)
- **Last updated:** 2026-03-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06466395

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06466395, "A Phase I Study of Hyper-CVAD In Combination With Venetoclax In Pediatric Patients With Relapsed or Refractory Acute Leukemias That Are of the Lymphoid Lineage Including Bi-Phenotypic or Undifferentiated Leukemias". Retrieved via AI Analytics 2026-08-02 from https://api.ai-analytics.org/clinical/NCT06466395. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*